Helix BioMedix, Inc. (HXBM)
USD 7.18
(0.0%)
USD 7.18
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 66.92 Thousand USD | -46.98% |
| 2022 | 126.24 Thousand USD | 0.0% |
| 2011 | 439.3 Thousand USD | 24.08% |
| 2010 | 354.03 Thousand USD | -95.07% |
| 2009 | 7.18 Million USD | 62.55% |
| 2008 | 4.41 Million USD | 1157.47% |
| 2007 | 351.35 Thousand USD | 37.33% |
| 2006 | 255.85 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 FY | 66.92 Thousand USD | -46.98% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 72.47 Million USD | 99.908% |
| Neon Bloom, Inc. | 1.22 Million USD | 94.542% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | 91.725% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -49.743% |
| Qrons Inc. | 1.48 Million USD | 95.504% |
| Rebus Holdings, Inc. | 5.24 Million USD | 98.723% |
| Skye Bioscience, Inc. | 14.07 Million USD | 99.524% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 99.887% |
| Adynxx, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 99.911% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | 66.721% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 99.293% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -143.973% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 99.874% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 99.302% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | 84.124% |
| SQZ Biotechnologies Company | 50.03 Million USD | 99.866% |
| Intellipharmaceutics International Inc. | 12 Million USD | 99.443% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 98.262% |
| Mesoblast Limited | 188.44 Million USD | 99.964% |
| Marizyme, Inc. | 26.67 Million USD | 99.749% |
| Genus plc | 485 Million USD | 99.986% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 98.854% |
| Pharming Group N.V. | 244.07 Million USD | 99.973% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | 96.67% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 97.34% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 98.239% |
| ContraFect Corporation | 32.53 Million USD | 99.794% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | 96.622% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 98.251% |
| IMV Inc. | 37.93 Million USD | 99.824% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 99.432% |
| MultiCell Technologies, Inc. | 1617.67 USD | -4037.37% |
| ONE Bio Corp. | 27.49 Million USD | 99.757% |
| Accustem Sciences Inc. | 1.07 Million USD | 93.799% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 99.914% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | 96.836% |
| Q BioMed Inc. | 8.13 Million USD | 99.177% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 99.919% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 98.699% |
| Biomind Labs Inc. | 1.49 Million USD | 95.534% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 99.944% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 99.26% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 99.636% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | 95.332% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | 52.898% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 98.835% |
| GB Sciences, Inc. | 5.41 Million USD | 98.765% |
| Alpha Cognition Inc. | 7.16 Million USD | 99.066% |
| HST Global, Inc. | 593.59 Thousand USD | 88.725% |
| CSL Limited | 18.62 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | 1.25 Million USD | 94.685% |
| Halberd Corporation | 728.71 Thousand USD | 90.816% |
| Enzolytics Inc. | 365.26 Million USD | 99.982% |
| Agentix Corp. | 2.51 Million USD | 97.334% |
| Resverlogix Corp. | 67.39 Million USD | 99.901% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | 92.02% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.985% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | 96.095% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 99.73% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 99.438% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 98.174% |
| AVAX Technologies, Inc. | 3.99 Million USD | 98.324% |
| Zenith Capital Corp. | 27.56 Thousand USD | -142.769% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.995% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | 71.956% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 98.208% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | 90.17% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 97.532% |
| Kadimastem Ltd | 3.5 Million USD | 98.09% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 99.867% |
| BioStem Technologies, Inc. | 15.9 Million USD | 99.579% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | 85.597% |
| LadRx Corporation | 2.2 Million USD | 96.959% |
| Cell Source, Inc. | 15.8 Million USD | 99.577% |
| Regen BioPharma, Inc. | 5.45 Million USD | 98.774% |
| Regen BioPharma, Inc. | 5.45 Million USD | 98.774% |
| NovAccess Global Inc. | 7.86 Million USD | 99.149% |
| Affymax, Inc. | 8.87 Million USD | 99.246% |
| Itoco Inc. | 1.65 Million USD | 95.951% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | 96.738% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 98.894% |
| Mobile Lads Corp. | 1.31 Million USD | 94.905% |
| CytoDyn Inc. | 127.89 Million USD | 99.948% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -60.121% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | 95.727% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 99.394% |
| SYBLEU INC | 681.41 Thousand USD | 90.178% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 98.903% |
| International Stem Cell Corporation | 5.27 Million USD | 98.732% |
| Bioxytran, Inc. | 3.24 Million USD | 97.94% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | 89.305% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 98.55% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 99.837% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 99.699% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | 96.695% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 98.778% |
| Neutra Corp. | 973.52 Thousand USD | 93.125% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 99.769% |
| PureTech Health plc | 125.58 Million USD | 99.947% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 98.219% |
| IXICO plc | 1.9 Million USD | 96.478% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 99.674% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.935% |
| CSL Limited | 18.62 Billion USD | 100.0% |
| Cellectis S.A. | 249.36 Million USD | 99.973% |